BPM
MYGN icon

Bowling Portfolio Management’s Myriad Genetics MYGN Stock Holding History

Bowling Portfolio Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-21,150
Closed -$973K – 377
2018
Q3 		$973K Buy
21,150
+3,108
+17% +$138K 0.14% 244
2018
Q2 		$674K Buy
+18,042
New +$609K 0.09% 276
2014
Q4 		– Sell
-110,222
Closed -$4.25M – 142
2014
Q3 		$4.25M Sell
110,222
-1,469
-1% -$54.8K 1% 51
2014
Q2 		$4.35M Buy
+111,691
New +$4.16M 1.03% 51

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bowling Portfolio Management's MYGN Position: Q4 2018 in Review

Bowling Portfolio Management sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 21,150 shares — an estimated $973K sold.

Bowling Portfolio Management first reported a position in MYGN in Q2 2014 and held it in 4 quarters. The position peaked at $4.35M in Q2 2014. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • Bowling Portfolio Management reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • Bowling Portfolio Management sold 21,150 Myriad Genetics shares in Q4 2018, an estimated $973K.
  • Bowling Portfolio Management first reported a position in Myriad Genetics in Q2 2014 and held it in 4 quarters.
  • Bowling Portfolio Management's Myriad Genetics position peaked at $4.35M in Q2 2014.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Bowling Portfolio Management's 13F filing for Q4 2018, filed 17 Jan 2019.